Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MOv18 IgE

Next Previous
Search
Drug Profile

MOv18 IgE

Alternative Names: MOv18; MOv18-IgE

Latest Information Update: 26 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Research UK; Kings College London
  • Developer Cancer Research UK; Epsilogen
  • Class Antibodies; Antineoplastics; Immunoglobulins; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ovarian cancer; Solid tumours

Most Recent Events

  • 03 Sep 2024 Phase-I clinical trials in Ovarian cancer (Late-stage disease, Second-line therapy or greater) in United Kingdom (IV), (NCT06547840)
  • 21 Aug 2024 MOv18 IgE is still in phase-I trials in Solid-tumours (In adolescents, In the elderly, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, In adults) in United Kingdom (IV, Infusion) (NCT02546921) (Epsilogen pipeline, August 2024)
  • 08 Jul 2024 UK MHRA accepts Clinical Trial Application (CTA) for MOv18 IgE, to initiate a phase Ib trial in Ovarian cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top